| Identification | Back Directory | [Name]
[4-[(Hydroxyamino)carbonyl]phenyl]carbamic acid [6-[(diethylamino)methyl]-2-naphthalenyl]methyl ester | [CAS]
497833-27-9 | [Synonyms]
CS-2025
Givinostat
Gavinostat
Givinostat(ITF-2357)
Givinostat(free base)
[6-(diethylaminomethyl)naphthalen-2-yl]methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate
[4-[(Hydroxyamino)carbonyl]phenyl]carbamic acid [6-[(diethylamino)methyl]-2-naphthalenyl]methyl ester
Carbamic acid, N-[4-[(hydroxyamino)carbonyl]phenyl]-, [6-[(diethylamino)methyl]-2-naphthalenyl]methylester | [Molecular Formula]
C24H27N3O4 | [MDL Number]
MFCD16619317 | [MOL File]
497833-27-9.mol | [Molecular Weight]
421.49 |
| Chemical Properties | Back Directory | [density ]
1.259 | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
8.97±0.10(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
Givinostat (ITF-2357) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat can be used for Duchenne muscular dystrophy (DMD) research[1]. | [Definition]
ChEBI: N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester is a carbamate ester. | [in vivo]
Givinostat (ITF2357) at 10 mg/kg is used as a positive control and, as expected, reduced serum TNFα by 60%. Strikingly, pretreatment of ITF3056 starting at 0.1 mg/kg significantly reduces the circulating TNFα by nearly 90%. To achieve a significant increase in serum IL-1β production, a higher dose of LPS is injected (10 mg/kg), and blood is collected after 4 h. Similarly, when pretreated with lower doses of Givinostat (ITF-2357) (1 or 5 mg/kg), there is a 22% reduction for 1 mg/kg and 40% for 5 mg/kg[1]. | [IC 50]
hHDAC3: 157 nM (IC50); HD1-B: 7.5 nM (IC50); HD1-A: 16 nM (IC50); HD2: 10 nM (IC50); hHDAC1: 198 nM (IC50); hHDAC11: 292 nM (IC50); hHDAC6: 315 nM (IC50); hHDAC2: 325 nM (IC50); hHDAC10: 340 nM (IC50); hHDAC7: 524 nM (IC50); hHDAC5: 532 nM (IC50); hHDAC9: 541 nM (IC50); hHDAC8: 854 nM (IC50); hHDAC4: 1059 nM (IC50) | [storage]
Store at -20°C | [References]
[1] Li S, et al. Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo. J Biol Chem. 2015 Jan 23;290(4):2368-78. DOI:10.1074/jbc.M114.618454
[2] Leoni F, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005 Jan-Dec;11(1-12):1-15. DOI:10.2119/2006-00005.Dinarello
[3] Wang YG, et al. Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation. World J Gastroenterol. 2015 Jul 21;21(27):8326-39. DOI:10.3748/wjg.v21.i27.8326 |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.yuhua99.com/ShowSupplierProductsList15748/0.htm |
|